News

According to an updated survival analysis of the large randomized phase III COMBI-v trial, co-inhibition of BRAF and MEK pathways with dabrafenib and trametinib continued to be superior to sole BRAF inhibition with vemurafenib in patients with unresectable metastatic melanoma at 3 years.

Early results from a pre-planned interim analysis in the KEYNOTE-052 phase II trial of first-line pembrolizumab in cisplatin-ineligible patients with metastatic urothelial cancer demonstrated antitumor activity.

William Cance, MD, has recently joined the University of Arizona Cancer Center (UACC) as Deputy Director.

Dafna Bar-Sagi, PhD, vice dean for science and chief scientific officer of NYU Langone Medical Center, and a senior member of its Perlmutter Cancer Center, was recently named a recipient of the Outstanding Investigator Award from the National Cancer Institute (NCI).

William G. Wierda, MD, PhD, discusses provided his expert insight on the frontline treatment of patients with CLL.

A recent phase III trial showed custirsen combined with docetaxel failed to significantly extend overall survival (OS) compared with docetaxel alone as a second-line treatment for patients with NSCLC.

Updated data from the CheckMate-205 trial demonstrated that nivolumab (Opdivo) had an objective response rate (ORR) of 73% in a cohort of patients with classical Hodgkin lymphoma.

Robert S. Alter, MD discusses optimal sequencing for bladder cancer agents and how he determines the appropriate treatment for patients.

First-line pembrolizumab demonstrated significant antitumor activity in cisplatin-ineligible patients with metastatic urothelial cancer.

Charles S. Fuchs, MD, MPH, has been appointed the new director and physician-in-chief of Smilow Cancer Hospital at Yale Cancer Center (YCC) in New Haven, Connecticut.

In patients with metastatic colorectal cancer (mCRC), the correlation between tumor location and improved survival varies based on stage of disease, according to a study.

An expert discusses the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.

Pegylated liposomal irinotecan (Onivyde) in combination with fluorouracil (5-FU) and leucovorin has been approved by the European Commission (EC) for patients with metastatic pancreatic adenocarcinoma.

James P. Allison, PhD, was recently presented with the Association of American Cancer Institutes (AACI) Distinguished Scientist Award in recognition of his extraordinary scientific accomplishments and contributions to cancer research.

In a recent study, single-agent olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with placebo in the maintenance setting for patients with advanced <em>BRAF</em>-positive ovarian cancer.

Denosumab (Xgeva) was shown to be noninferior to zoledronic acid (Zometa) at delaying skeletal-related events (SREs) for patients with multiple myeloma.

In an interview with<em> Targeted Oncology</em>, Kimberly L. Blackwell, MD, discusses the latest therapeutic developments for patients with HER2-positive breast cancer while providing insight on the hurdles that still remain.

Pembrolizumab (Keytruda) has received FDA approval for the frontline treatment of patients with metastatic non&shy;&ndash;small cell lung cancer (NSCLC) whose tumors have &ge;50% PD-L1 expression based on an FDA-approved test and who do not harbor EGFR or ALK aberrations.

The FDA has updated the label for enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC) to include new data from the phase II TERRAIN study, according to the codevelopers of the androgen receptor inhibitor, Astellas and Pfizer.

Mutation discordance between primary and metastatic sites in colorectal cancer (CRC) may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.

Findings of the phase III KEYNOTE-045 trial showed pembrolizumab (Keytruda) demonstrated improved survival compared with chemotherapy in previously treated patients with advanced urothelial cancer.

Nivolumab (Opdivo) has received a priority review designation from the FDA as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma.

Nationally recognized oncologist Nancy E. Davidson, MD, has accepted the position of Executive Director of Clinical Oncology at the Fred Hutch/University of Washington (UW) Cancer Consortium in Seattle, Washington. Davidson was previously Director of the the University of Pittsburgh Cancer Institute (UPCI).

The current treatment landscape for relapsed and refractory multiple myeloma is so promising, oncologists should not hesitate to consider integrating novel therapies into multiple myeloma management, Kenneth C. Anderson, MD, said.

Brad S. Kahl, MD, sheds light on the distinctive clinical features of MCL.

Richard R. Furman, MD emphasizes that physicians should follow their best independent judgment regarding therapy selection in CLL, regardless of FDA approval.

According to phase I data presented at the 2016 ESMO Congress, a&nbsp;novel HER2-targeting antibody-drug conjugate showed promising antitumor activity across multiple tumor types, including HER2-postive breast cancer.

Men with bone-metastatic castration-resistant prostate cancer (mCRPC) appeared to derive additional benefits from treatment with radium-223 with concomitant bone-targeted therapies.

Confirming the results of an earlier phase II study, findings from the FALCON trial showed first-line treatment with fulvestrant led to significantly better progression-free survival compared with anastrozole for patients with hormone receptor (HR)-positive advanced breast cancer.